IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
IRONWOOD PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | Q4 25 | Q3 25 | Q2 25 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative arrangement, other agreements | $0 | $0 | $87.00K | $222.00K | $358.00K | $516.00K | $601.00K | $755.00K | $540.00K | $580.00K | $570.00K | $365.00K | 0.0% |
| Collaborative arrangements revenue | – | – | – | – | – | – | – | – | $107.38M | $104.06M | $107.20M | $108.64M | – |
| Collaborative arrangement, development and commercialization agreements | – | – | – | – | – | – | – | – | $603.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ironwood Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.